1. Academic Validation
  2. An ANXA11 P93S variant dysregulates TDP-43 and causes corticobasal syndrome

An ANXA11 P93S variant dysregulates TDP-43 and causes corticobasal syndrome

  • Res Sq. 2023 Oct 19:rs.3.rs-3462973. doi: 10.21203/rs.3.rs-3462973/v1.
Allison Snyder 1 Veronica H Ryan 2 James Hawrot 1 Sydney Lawton 1 Daniel M Ramos 2 Y Andy Qi 2 Kory Johnson 3 Xylena Reed 2 Nicholas L Johnson 4 Aaron W Kollasch 5 Megan Duffy 6 Lawren VandeVrede 7 J Nicholas Cochran 8 Bruce L Miller 7 Camilo Toro 9 Bibiana Bielekova 10 Jennifer S Yokoyama 7 Debora S Marks 11 Justin Y Kwan 12 Mark R Cookson 6 Michael E Ward 1
Affiliations

Affiliations

  • 1 Neurogenetics Branch, National Institute of Neurological Disorders and Stroke.
  • 2 Center for Alzheimer's and Related Dementias, National Institutes of Health.
  • 3 Intramural Bioinformatics, National Institute of Neurological Disorders and Stroke.
  • 4 Data Tecnica International LLC.
  • 5 Department of Systems Biology, Harvard Medical School.
  • 6 Cell Biology and Gene Expression Section, Laboratory of Neurogenetics, National Institute on Aging.
  • 7 Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco.
  • 8 HudsonAlpha Institute for Biotechnology.
  • 9 Undiagnosed Diseases Program, National Human Genome Research Institute.
  • 10 Neuroimmunological Diseases Section, National Institute of Allergy and Infectious Disease.
  • 11 Department of Systems Biology, Harvard Medical School, Boston.
  • 12 Office of the Clinical Director, National Institute of Neurological Disorders and Stroke.
Abstract

As genetic testing has become more accessible and affordable, variants of uncertain significance (VUS) are increasingly identified, and determining whether these variants play causal roles in disease is a major challenge. The known disease-associated Annexin A11 (ANXA11) mutations result in ANXA11 aggregation, alterations in lysosomal-RNA granule co-trafficking, and TDP-43 mis-localization and present as amyotrophic lateral sclerosis or frontotemporal dementia. We identified a novel VUS in ANXA11 (P93S) in a kindred with corticobasal syndrome and unique radiographic features that segregated with disease. We then queried neurodegenerative disorder clinic databases to identify the phenotypic spread of ANXA11 mutations. Multi-modal computational analysis of this variant was performed and the effect of this VUS on ANXA11 function and TDP-43 biology was characterized in iPSC-derived neurons. Single-cell Sequencing and proteomic analysis of iPSC-derived neurons and microglia were used to determine the multiomic signature of this VUS. Mutations in ANXA11 were found in association with clinically diagnosed corticobasal syndrome, thereby establishing corticobasal syndrome as part of ANXA11 clinical spectrum. In iPSC-derived neurons expressing mutant ANXA11, we found decreased colocalization of lysosomes and decreased neuritic RNA as well as decreased nuclear TDP-43 and increased formation of cryptic exons compared to controls. Multiomic assessment of the P93S variant in iPSC-derived neurons and microglia indicates that the pathogenic omic signature in neurons is modest compared to microglia. Additionally, omic studies reveal that immune dysregulation and interferon signaling pathways in microglia are central to disease. Collectively, these findings identify a new pathogenic variant in ANXA11, expand the range of clinical syndromes caused by ANXA11 mutations, and implicate both neuronal and microglia dysfunction in ANXA11 pathophysiology. This work illustrates the potential for iPSC-derived cellular models to revolutionize the variant annotation process and provides a generalizable approach to determining causality of novel variants across genes.

Keywords

ANXA11; TDP-43; corticobasal syndrome; variant of uncertain significance.

Figures
Products